Soleus Capital, LLC insider trades: Parabilis Medicines (PBLS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Soleus Capital, LLC reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | PBLS | ↑ Buy | 500,000 | $20.00 | $10.0M | Indirect | Jun 29, 2026 (18d) |
| May 5, 2020 | LYRA | ↑ Buy | 155,000 | $16.00 | $2.5M | Indirect | May 15, 2020 (10d) |
| May 5, 2020 | LYRA | ↓ Sell | 16,909 | $16.00 | $271K | Indirect | May 15, 2020 (10d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PBLS insiders
Open-market trades in the last 12 months
About Soleus Capital, LLC's insider trades
Soleus Capital, LLC is a 10% owner of Parabilis Medicines (PBLS). Since May 5, 2020, it has reported 2 open-market purchases worth $12.5M and 1 sale worth $271K on SEC Form 4. In the last 12 months: 1 buy ($10.0M).
Its filings also include conversions (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PBLS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.